1)Thalmann GN, Markwalder R, Walter B, et al:Long-term experience with bacillus Calmette-Guérin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol 168:1381-1385, 2002
2)Sharpe JR, Duffy G and Chin JL:Intrarenal bacillus Calmette-Guérin therapy for upper urinary tract carcinoma in situ. J Urol 149:457-460, 1993
3)Nonomura N, Ono Y, Nozawa M, et al:Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract. Eur Urol 38:701-705, 2000
4)Okubo K, Ishitoya S, Maeda H, et al:Intrarenal bacillus Calmette-Guérin therapy for carcinoma in situ of the upper urinary tract. Acta Urol Jpn 88:386-390, 1997
5)Martíinez-Piñeiro JA, Flores N, Isorna S, et al:Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27mg in superficial bladder cancer. BJU International 89:671-680, 2002
6)Bassi P, Spinadin R, Carando R, et al:Modified induction course:A solution to side-effects? Eur Urol 37:31-32, 2000
7)Patrik A, Marianne F and Sten H:Intravesical bacillus Calmette-Guérin therapy:experience with a reduced dwell-time in patients with pronounced side-effects. BJU International 96:1290-1293, 2005